TRIPLE NEGATIVE BREAST CANCER

Aug 08, 2024

October, a month awash in pink, stands as a global testament to Breast Cancer Awareness Month. Pink ribbons flutter in the breeze, pink tee-shirts fill the streets, and pink banners drape buildings. This vibrant display of pink is more than a color; it’s a unified call to action, dedicating a month to raising aware...

Jun 25, 2024

Triple-negative breast cancer (TNBC) constitutes about 10-15% of all breast cancer cases with nearly 44,000 incident cases in the United States in 2023, as per Delveinsight’s estimates. It is a rare but aggressive form of breast cancer. Treatment for TNBC is more limited than for other breast cancer types. C...

Jul 28, 2020

AZ, Daiichi put their trust into TROP2-based drugs, inks an oncology deal to together develop and commercialize DS-1062 AstraZeneca has inked an oncology deal with Daiichi Sankyo to jointly develop and commercialize an antibody-drug conjugate DS-1062 (trastuzumab deruxtecan), worldwide except in Japan. Daiichi ...

Oct 16, 2019

HR-positive/HER2-negative breast cancer treatment landscape focuses on the complexity of the specific cancer type and the treatment differ according to the biomarker status. The trend suggests a greater bend towards personalized medicine based upon patient biomarkers and physiologic characteristics In our last a...

Aug 27, 2019

Zogenix pays USD 250M upfront Modis clinical drug Zogenix, a pharmaceutical company focused on advancing rare disease therapies, has collaborated with the Modis therapeutics. Modis Therapeutics is a company aiming to advance in mitochondrial biology to develop disease-modifying therapies for rare genetic diseas...

Nov 08, 2018

Gordon and Betty Moore Foundation gives USD 85 Million to stop delayed, erroneous diagnostics The Gordon and Betty Moore Foundation is putting up money for improving diagnostics. The Foundation focuses on a plethora of areas, including those outside of healthcare, such as environmental conservation. It has an annua...

Oct 22, 2018

[caption id="attachment_3465" align="alignnone" width="800"] INSIGHTS ON TRIPLE NEGATIVE BREAST CANCER[/caption]   To know more about TRIPLE NEGATIVE BREAST CANCER request for sample pages: https://www.delveinsight.com/dev-sample.php?form_name=Triple-Negative-Breast-Cancer-(TNBC)---Market-Insight,-Epidemi...

Apr 27, 2017

Merck sells biosimilars business to Fresenius Merck has divested its biosimilars business to fellow German drug maker Fresenius in a deal potentially worth 670 million euros. The drug maker said the move is aligned with a strategy of focusing on innovative medicines while enabling it to exploit its biosimilars portf...